iRadimed Corporation (NASDAQ:IRMD) Sees Large Increase in Short Interest

iRadimed Corporation (NASDAQ:IRMD) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 388,071 shares, a growth of 25.1% from the December 15th total of 310,250 shares. Currently, 4.8% of the shares of the company are short sold. Based on an average daily volume of 79,534 shares, the short-interest ratio is currently 4.9 days. Based on an average daily volume of 79,534 shares, the short-interest ratio is currently 4.9 days. Currently, 4.8% of the shares of the company are short sold.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Roth Capital set a $90.00 target price on shares of iRadimed in a research report on Friday, October 31st. Zacks Research raised iRadimed to a “hold” rating in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 target price on shares of iRadimed in a research note on Monday, November 3rd. Finally, Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, iRadimed currently has an average rating of “Moderate Buy” and an average target price of $87.33.

iRadimed Stock Performance

NASDAQ IRMD traded down $1.24 during trading on Tuesday, hitting $100.77. The stock had a trading volume of 4,070 shares, compared to its average volume of 80,314. The company has a market capitalization of $1.28 billion, a PE ratio of 61.15 and a beta of 1.09. iRadimed has a 12 month low of $47.48 and a 12 month high of $103.06. The company’s 50-day moving average price is $94.73 and its two-hundred day moving average price is $78.78.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The firm had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, equities analysts anticipate that iRadimed will post 1.66 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The business also recently declared a special dividend, which was paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th were issued a dividend of $0.50 per share. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio is 41.21%.

Insider Activity at iRadimed

In related news, CFO John Glenn sold 15,000 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the sale, the chief financial officer owned 7,362 shares in the company, valued at approximately $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $97.45, for a total value of $487,250.00. Following the sale, the chief executive officer directly owned 2,272,500 shares in the company, valued at $221,455,125. The trade was a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 55,000 shares of company stock worth $5,077,100. Company insiders own 36.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Johnson Investment Counsel Inc. boosted its stake in shares of iRadimed by 0.7% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock valued at $1,839,000 after purchasing an additional 187 shares during the last quarter. Summit Global Investments lifted its holdings in iRadimed by 2.7% in the third quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock valued at $508,000 after buying an additional 188 shares during the period. CWM LLC lifted its holdings in iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 211 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 234 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in iRadimed by 30.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 2,056 shares of the medical equipment provider’s stock worth $123,000 after acquiring an additional 477 shares during the period. 92.34% of the stock is owned by institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.